Physician profile
Magdi E Sayegh
NPI 1013901412
$4,000.78
in general payments reported to CMS, 2019-2025
38 companies · $575 in 2025
The $575 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $266 · 2021: $456 · 2022: $1,027 · 2023: $614 · 2024: $599 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.75 |
| Education | $126.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $448.64 | 2019-2025 | Veozah |
| Abbvie INC. | $437.77 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $366.15 | 2021-2025 | |
| Pfizer INC. | $234.26 | 2019-2025 | |
| Exeltis, USA INC. | $219.10 | 2020-2025 | Slynd |
| Therapeuticsmd, INC. | $188.04 | 2019-2022 | |
| Amgen INC. | $173.69 | 2019-2025 | Evenity, Prolia, Prolia |
| Organon LLC | $152.42 | 2021-2025 | Nexplanon |
| Millicent US INC | $151.03 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Merck Sharp & Dohme LLC | $139.68 | 2019-2024 | Gardasil 9, Gardasil |
| Scynexis, INC. | $133.20 | 2022 | |
| Agile Therapeutics, INC. | $128.22 | 2022-2024 | Twirla |
| Coopersurgical, INC. | $121.04 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Mylan Pharmaceuticals INC. | $116.68 | 2021-2022 | |
| Gilead Sciences, INC. | $105.71 | 2022-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $80.35 | 2019-2020 | |
| Daiichi Sankyo INC. | $80.18 | 2021-2022 | |
| Hologic Sales and Service, LLC | $76.59 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Shield Therapeutics INC | $67.47 | 2023 | Accrufer |
| Medtronic, INC. | $67.21 | 2021-2025 | Truclear |
| Exact Sciences Corporation | $63.69 | 2023-2025 | Cologuard Collection Kit |
| Biogen, INC. | $49.86 | 2025 | Zurzuvae |
| Minerva Surgical, INC | $45.22 | 2019 | |
| Radius Health, INC. | $44.67 | 2019-2025 | |
| Dexcom, INC. | $43.51 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $39.82 | 2022 | |
| Currax Pharmaceuticals LLC | $35.36 | 2022 | |
| Duchesnay USA Incorporated | $23.10 | 2019 | |
| Novo Nordisk INC | $22.77 | 2025 | Wegovy |
| Meditrina | $21.81 | 2021 | |
| Organogenesis INC. | $20.74 | 2022 | |
| Roche Diagnostics Corporation | $17.20 | 2021 | |
| Sumitomo Pharma America, INC. | $15.80 | 2023 | Myfembree |
| Lilly USA, LLC | $14.65 | 2025 | Zepbound |
| Cepheid | $14.32 | 2025 | |
| Lupin INC. | $14.00 | 2019 | |
| Allergan, INC. | $13.64 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdi Sayegh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.